InvestSMART

Clinuvel Pharmaceuticals Limited (ASX: CUV) - Announcements

Current share price for CUV : $7.120 0.05 (0.71%)+

ASX company news and announcements for Clinuvel Pharmaceuticals Limited (CUV) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clinuvel Pharmaceuticals Limited (CUV) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clinuvel Pharmaceuticals Limited (CUV), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clinuvel Pharmaceuticals Limited (CUV)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$359 CLINUVEL Annual Results - Investor Webinar 29 Aug 2025 9:08AM $12.530 $7.120 fallen by 43.18%
$359 Investor Presentation 28 Aug 2025 9:37AM $13.550 $7.120 fallen by 47.45%
$359 Corporate Governance Statement 28 Aug 2025 9:36AM $13.550 $7.120 fallen by 47.45%
$359 Appendix 4G 28 Aug 2025 9:36AM $13.550 $7.120 fallen by 47.45%
$359 Dividend/Distribution - CUV 28 Aug 2025 9:36AM $13.550 $7.120 fallen by 47.45%
$359 CLINUVEL delivers ninth consecutive revenues growth & profit 28 Aug 2025 9:35AM $13.550 $7.120 fallen by 47.45%
$359 Appendix 4E and Annual Report to Shareholders 2025 28 Aug 2025 9:34AM $13.550 $7.120 fallen by 47.45%
$359 CLINUVEL preparing upgrade of ADR program, NASDAQ uplist 22 Aug 2025 9:30AM $11.990 $7.120 fallen by 40.62%
$359 CLINUVEL Annual Results - Investor Webinar 21 Aug 2025 12:17PM $11.950 $7.120 fallen by 40.42%
$359 Bioshares Biotech Summit presentation 7 Aug 2025 9:24AM $12.280 $7.120 fallen by 42.02%
$359 Presentation to BTIG Biotech Conference 30 Jul 2025 12:06PM $13.200 $7.120 fallen by 46.06%
$359 Notification of cessation of securities - CUV 2 Jul 2025 8:21AM $10.120 $7.120 fallen by 29.64%
$359 German Non-deal Roadshow Presentation 24 Jun 2025 8:45AM $9.440 $7.120 fallen by 24.58%
$359 Ceasing to be a substantial holder 19 Jun 2025 8:16AM $9.690 $7.120 fallen by 26.52%
$359 Study confirms NB-UVB needed to activate repigmentation 18 Jun 2025 9:35AM $9.760 $7.120 fallen by 27.05%
$359 Becoming a substantial holder 18 Jun 2025 8:19AM $9.760 $7.120 fallen by 27.05%
$359 CLINUVEL management update 13 Jun 2025 9:35AM $10.180 $7.120 fallen by 30.06%
$359 SCENESSE successfully administered to paediatric EPP patient 13 Jun 2025 8:58AM $10.180 $7.120 fallen by 30.06%
$359 SCENESSE in Vitiligo - A Global Update 4 Jun 2025 10:07AM $10.095 $7.120 fallen by 29.47%
$359 SCENESSE EPP data featured at EADV Symposium 22 May 2025 8:57AM $10.520 $7.120 fallen by 32.32%
$359 Ceasing to be a substantial holder 9 May 2025 8:24AM $11.270 $7.120 fallen by 36.82%
$359 CUV recruits 200 patients in Phase III vitiligo trial CUV105 7 May 2025 8:41AM $11.300 $7.120 fallen by 36.99%
$359 Notification regarding unquoted securities - CUV 23 Apr 2025 9:00AM $10.590 $7.120 fallen by 32.77%
$359 Notification of cessation of securities - CUV 9 Apr 2025 8:22AM $10.660 $7.120 fallen by 33.21%
$359 Section 708A Cleansing Statement 7 Apr 2025 8:55AM $10.540 $7.120 fallen by 32.45%

76 - 100 of 881 results

Page 4 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.